MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

NCT03928704 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 274

Last updated 2025-12-24

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).

Conditions

  • Nonradiographic Axial Spondyloarthritis

Interventions

DRUG

Bimekizumab

Subjects will receive bimekizumab at pre-specified time-points.

OTHER

Placebo

Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-25
Primary Completion
2022-06-29
Completion
2023-04-17
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Bulgaria
  • China
  • Czechia
  • France
  • Germany
  • Hungary
  • Japan
  • Poland
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03928704 on ClinicalTrials.gov